MedicareInsights

What changed in Medicare policy this quarter?

Data through Through July 2026 · Updated July 1, 2026 curated

CMS Launches Medicare GLP-1 Bridge, Expanding Access to GLP-1 Medications (July 1, 2026) leads the quarter. 7 of 12 tracked CMS actions are rated high-impact — the GLP-1, 2027-rate, and star-methodology threads dominate.

Tracked CMS actions, most recent first

DateImpactActionWhy it matters
2026-07-01 HIGH CMS Launches Medicare GLP-1 Bridge, Expanding Access to GLP-1 Medications
CMS announced the Medicare GLP-1 Bridge initiative to expand beneficiary access to GLP-1 medications, a major shift for Part D formulary strategy and C-SNP diabetes/cardio populations.		 GLP-1 access is coming to Medicare — plans must model formulary, bid, and adherence impacts now.
2026-06-12 MED CMS Proposed Rule Locks In Lower Prices for the Drug Price Negotiation Program
CMS proposed a rule to lock in lower negotiated prices and foster innovation under the Medicare Drug Price Negotiation Program, ahead of the 15 additional negotiated drugs taking effect January 1, 2027.		 Second negotiation cycle (15 drugs incl. GLP-1s) hits formularies in 2027 — this rule shapes how MFPs flow to the pharmacy counter.
2026-04-06 HIGH CMS Issues Final 2027 Medicare Advantage Rate Announcement
CMS finalized a net average payment increase of 2.48% (over $13B) for CY 2027 — up sharply from the 0.09% proposed in the Advance Notice. Including expected risk score trend, average revenue growth approaches 4.98%.		 Plans get a moderate pay raise in 2027 — better than the near-flat Advance Notice, easing benefit-cut pressure at AEP 2026.
2026-03-28 HIGH CMS Releases 2026 Part C & D Star Ratings Methodology Updates
CMS confirmed the Kidney Health Evaluation (KED) measure will carry a 3× weight multiplier in 2027 star calculations. Plans with diabetes populations below 60% KED score will face composite rating pressure.		 If your plan's diabetes patients aren't getting kidney tests, your stars will drop in 2027.
2026-03-15 HIGH CMS Imposes $2.3M Civil Money Penalty on Humana for Prior Auth Violations
CMS issued a Civil Money Penalty (CMP) against Humana for systematic delays in prior authorization decisions exceeding the 14-day standard, affecting approximately 84,000 Medicare beneficiaries in FL and TX.		 Humana fined $2.3M — PA delays directly lower CAHPS scores, which now carry 4× star weight.
2025-01-17 HIGH IRA Drug Negotiation Round 2: HHS Announces 15 Additional Drugs for 2027
HHS identified the next 15 drugs subject to IRA price negotiation for initial price applicability year 2027, headlined by semaglutide (Ozempic/Rybelsus/Wegovy), plus Trelegy Ellipta, Xtandi, Otezla, Ibrance, and others. Negotiated prices take effect January 1, 2027.		 15 more blockbuster drugs — including the GLP-1 semaglutide family — get negotiated prices effective 2027; formulary and bid impacts land in the 2027 cycle.
2026-02-28 HIGH CMS Publishes 2027 Advance Notice for MA/Part D — Near-Flat +0.09% Proposal
The 2027 Advance Notice proposed a near-flat +0.09% average payment change (~$700M), later finalized at +2.48% (~$13B) in the April 2026 Rate Announcement after updated FFS cost data. V28 risk model and SNP model updates continue.		 Plans planning their 2027 bids know their revenue baseline — 4.33% increase vs 2026.
2026-02-20 MEDIUM CMS Finalizes New Prior Authorization Transparency Rule
Effective Jan 2027, all MA plans must report prior authorization denial rates, approval times, and appeal outcomes quarterly to CMS. Data will be publicly posted on Medicare.gov.		 Plans that deny a lot of prior auths will soon be publicly compared — beneficiaries will shop accordingly.
2026-02-14 MEDIUM CMS Approves 14 New FIDE-SNP Contracts for 2026
CMS approved 14 new Fully Integrated Dual Eligible Special Needs Plan (FIDE-SNP) contracts for 2026, primarily in MS, AL, LA, and AR — states with the highest dual-eligible density and lowest current D-SNP penetration.		 New FIDE-SNPs opening in the Deep South — biggest growth opportunity for carriers in the dual-eligible market.
2026-01-31 HIGH CMS Confirms $2,100 Annual Part D OOP Threshold (CY2026) — First Payments Processed
CMS confirmed that the Inflation Reduction Act $2,100 annual Part D OOP threshold (CY2026) began with January 2026 claims processing. Approximately 3.2M beneficiaries already exceeded prior year spending by month-end.		 The $2,100 annual OOP threshold is live — 3.2M members approaching cap in January. Oncology patients saving the most.
2026-01-20 MEDIUM CMS Issues AIPD Warning Letters to 23 Plans for Star Rating Manipulation
CMS sent warning letters to 23 Medicare Advantage plans under the Automated Identifying Potential Data Discrepancies (AIPD) program for possible gaming of HEDIS and CAHPS survey administration processes.		 23 plans caught potentially gaming star ratings — enforcement actions could follow and ratings may be reduced.
2026-01-08 MEDIUM CMS Releases 2026 Medicare Part D National Average Premium: $36.78
The 2026 national average Part D monthly premium is $36.78, down from $40.12 in 2025. The decrease is driven by IRA changes to the catastrophic phase, eliminating member cost-sharing above the OOP cap.		 Part D premiums fell $3.34/month — the IRA is already bending the cost curve for drug coverage.
✉ Notify me when this updates

So what / Now what

Three 2026 threads matter most for plan economics: GLP-1 coverage expansion (formulary and C-SNP strategy), the 2027 rate cycle (benchmark and V28 phase-in), and star methodology tightening (bonus revenue). Each is dated below so analyses can be cited against a specific announcement.

Provenance — CMS policy developments
Source file
CMS.gov newsroom, Federal Register, CMS fact sheets (curated)
Vintage
Through July 2026
Last updated
July 1, 2026
Refresh cadence
Ad hoc, reviewed monthly
Method
Analyst-curated summaries of CMS announcements with impact ratings.
Known limitations
Curated selection, not a complete feed. Impact ratings are editorial.